Ionis Pharmaceuticals and Roche reported positive interim Phase 3 results for sefaxersen, which met its primary endpoint by improving proteinuria versus placebo. IgA nephropathy can lead to end-stage kidney disease in up to 50% of patients, and the study will continue measuring kidney function.
Key Highlights
- Sefaxersen delivered statistically significant and clinically meaningful proteinuria improvement against placebo in the IMAgINATION study.
- The investigational treatment is a once-monthly subcutaneous injection intended for self-administration.
- Roche licensed sefaxersen from Ionis and may provide regulatory and sales milestones plus tiered royalties on net sales.
Sefaxersen Meets Primary Endpoint
Ionis Pharmaceuticals Inc. (NASDAQ: IONS) is a major pharmaceuticals company. The study achieved its primary endpoint, with sefaxersen producing statistically significant and clinically meaningful improvement in proteinuria compared with placebo. The result was measured through the 24-hour urine protein-to-creatinine ratio, or UPCR. The treatment is designed as a once-monthly subcutaneous injection that people can administer themselves. Its safety and tolerability profile remained consistent with earlier data, and no new safety signals were identified. The trial is randomized, double-blind and placebo-controlled. It is continuing in blinded form to assess changes in kidney function through estimated glomerular filtration rate. Interim findings are expected to be presented at a medical congress and shared with health authorities. Roche licensed sefaxersen from Ionis for complement-mediated diseases.
FAQs
Q: What did Ionis Pharmaceuticals report about sefaxersen?
A: Ionis Pharmaceuticals and Roche reported positive interim Phase 3 results for sefaxersen in primary IgA nephropathy. The study met its primary endpoint through proteinuria improvement versus placebo.
Q: How is sefaxersen administered in the IgA nephropathy study?
A: Sefaxersen is an investigational subcutaneous injection designed for once-monthly dosing. The treatment is also intended to support self-administration by people with IgA nephropathy.
Q: What happens next in the IMAgINATION study?
A: The IMAgINATION study will remain blinded while researchers evaluate kidney-function changes. Interim results are expected to be presented at a medical congress and shared with health authorities.
Download Free Report – Explore 3 Stock Ideas & Industry Insights
Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.
All investments involve risk—consider independent advice before making any investment decisions.
View 3 Research Reports
Disclaimer:
Kalkine Equities LLC, with Delaware File Number 4697384, Foreign Qualification Registration in California File Number 202109211078, and Texas File Number 805521396, is authorized to provide general advice only. The information on https://kalkine.com/ does not take into account any of your investment objectives, financial situation or needs. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. The link to our Terms and Conditions and Privacy Policy has been provided for your reference. On the date of publishing the reports (mentioned on the website), employees and/or associates of Kalkine do not hold positions in any of the stocks covered on the website. These stocks can change any time and readers of the reports should not consider these stocks as advice or recommendations later.